Metraipolis › archive › dc_bde17c2394bb

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells — Europe PMC PMID:32866210

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32866210
DOI
10.1371/journal.ppat.1008845
License (as archived)
CC0-1.0
Archived
2026-11-07T15:00:28.500Z
SHA-256 of the archived text
b4f9859ed4096619db706fd65cc1eabfd1ff1e82714e6646f11c2af4cf2a4ddf
Stable URL of this page
https://metraipolis.com/documento/dc_bde17c2394bb

How to cite

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells — Europe PMC PMID:32866210 — Europe PMC (en), https://europepmc.org/article/MED/32866210 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_bde17c2394bb (Metraipolis archive dc_bde17c2394bb, sha256 b4f9859ed4096619db706fd65cc1eabfd1ff1e82714e6646f11c2af4cf2a4ddf)
BibTeX
@misc{dcbde17c2394bb,
  title = {Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells — Europe PMC PMID:32866210},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32866210},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_bde17c2394bb; sha256 b4f9859ed4096619db706fd65cc1eabfd1ff1e82714e6646f11c2af4cf2a4ddf},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32866210. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Modified vaccinia virus Ankara (MVA) is an approved smallpox vaccine and a promising vaccine vector for other pathogens as well as for cancer therapeutics with more than 200 current or completed clinical trials. MVA was derived by passaging the parental Ankara vaccine virus hundreds of times in chick embryo fibroblasts during which it lost the ability to replicate in human and most other mammalian cells. Although this replication deficiency is an important safety feature, the genetic basis of the host restriction is not understood. Here, an unbiased human genome-wide RNAi screen in human A549 cells revealed that the zinc-finger antiviral protein (ZAP), previously shown to inhibit certain RNA viruses, is a host restriction factor for MVA, a DNA virus. Additional studies demonstrated enhanced MVA replication in several human cell lines following knockdown of ZAP. Furthermore, CRISPR-Cas9 knockout of ZAP in human A549 cells increased MVA replication and spread by more than one log but had no effect on a non-attenuated strain of vaccinia virus. The intact viral C16 protein, which had been disrupted in MVA, antagonized ZAP by binding and sequestering the protein in cytoplasmic punctate structures. Studies aimed at exploring the mechanism by which ZAP restricts MVA replication in the absence of C16 showed that knockout of ZAP had no discernible effect on viral DNA or individual mRNA or protein species as determined by droplet digital polymerase chain reaction, deep RNA sequencing and mass spectrometry, respectively. Instead, inactivation of ZAP reduced the number of aberrant, dense, spherical particles that typically form in MVA-infected human cells, suggesting that ZAP has a novel role in interfering with a late step in the assembly of infectious MVA virions in the absence of the C16 protein.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2020 (prima pubblicazione 2020-08-31).
Identificativi: PMID 32866210 · PMCID PMC7485971 · DOI 10.1371/journal.ppat.1008845.
Pagina: https://europepmc.org/article/MED/32866210 — https://doi.org/10.1371/journal.ppat.1008845. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T14:56:05.986Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.